Breakthrough cancer drug doubles survival in trial

A groundbreaking cancer drug has shown promising results in doubling survival rates for patients with advanced head and neck cancer, according to a recent clinical trial. This immunotherapy drug, pembrolizumab, has significantly improved outcomes for patients like Laura Marston, who was given dire survival chances after being diagnosed with advanced tongue cancer six years ago. The drug, administered before and after surgery, helps the body's immune system target and attack cancer cells, leading to a significant increase in the length of time patients remain cancer-free.